Ichor is a privately held emerging biotechnology company, leveraging its proprietary TriGrid™ System to enable electroporation-mediated DNA drug products.
Ichor has raised paid-in capital from equity financing from undisclosed private and institutional investors. The company has leveraged a mix of corporate and academic collaborations and grant and contract funding to advance the technology for a variety of applications. To date, Ichor has received committed grant or contract funding in excess of $30 million and has applied for significant additional funding.
As a privately held company, Ichor does not disclose detailed financial information.